Health
Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study
New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a mean 5.08 reduction on the VAS pain scale, in patients with severe pancreatic cancer pain 100% of responders (n=7) 1 showed zero opioid use at their 3-month post-procedure follow-up2 Quality of life markers further improved including sleep quality, energy level and ability to lead normal daily and leisure time activities and reduced tension, vomiting and constipation THE
About this update from Autonomix Medical, Inc.
[{"type":"image","alt":"Autonomix Medical, Inc.","displaySize":"","headline":null,"caption":"Autonomix Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":174,"url":"https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yXZC_k658ygjAcliUe7Yow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6","width":300,"height":174}},"lazy":false},{"type":"text","content":"New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a mean 5.08 reduction on the VAS pain scale, in patients with severe pancreatic cancer pain","length":216,"tagName":"p"},{"type":"text","content":"100% of responders (n=7) 1 showed zero opioid use at their 3-month post-procedure follow-up2","length":92,"tagName":"p"},{"type":"text","content":"Quality of life markers further improved including sleep quality, energy level and ability to lead normal daily and leisure time activities and reduced tension, vomiting and constipation","length":186,"tagName":"p"},{"type":"text","content":"THE WOODLANDS, TX, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced new longer-term post hoc data from its initial trial phase of its first-in-human study proof-of-concept evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with severe pancreatic cancer pain.","length":508,"tagName":"p"},{"type":"text","content":"“These longer-term data build on the compelling results from PoC 1 and appear to show the sustained benefit our technology can deliver to patients with severe cancer pain. Importantly, 100 percent of responders were opioid-free three months post-procedure, reinforcing the potential of our approach as a non-opioid alternative for a highly opioid-dependent population. The durability of effect and quality-of-life improvements further support the value proposition of our platform as we expand into additional visceral cancer pain indications in PoC 2 and beyond,” commented Brad Hauser, CEO of Autonomix.",...